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RNA-sequencing-based comparative analysis of
human hepatic progenitor cells and their niche from
alcoholic steatohepatitis livers
An Ceulemans*,1,5, Stefaan Verhulst2,5, Matthias Van Haele1, Olivier Govaere3,4, Juan-Jose Ventura1, Leo A van Grunsven2,5 and
Tania Roskams*,1,5
Hepatic progenitor cells (HPCs) are small cells with a relative large oval nucleus and a scanty cytoplasm situated in the canals of
Hering that express markers of (immature) hepatocytes and cholangiocytes. HPCs are present in large numbers in alcoholic
steatohepatitis (ASH), one of the leading causes of chronic liver disease. To date, the mechanisms responsible for proliferation and
differentiation of human HPCs are still poorly understood and the role of HPCs in ASH development is unknown. In this study, we
aimed to characterise human HPCs and their interactions with other cells through comparison, on both protein and RNA level, of
HPC-enriched cell populations from adult human liver tissue using different isolation methods. Fresh human liver tissue was
collected from ASH explant livers and HPC-enriched cell populations were obtained via four different isolation methods: side
population (SP), epithelial cell adhesion molecule (EpCAM) and trophoblast antigen 2 (TROP-2) membrane marker isolation and
laser capture microdissection. Gene expression profiles of fluorescent-activated cell-sorted HPCs, whole liver extracts and laser
microdissected HPC niches were determined by RNA-sequencing. Immunohistochemical evaluation of the isolated populations
indicated the enrichment of HPCs in the SP, EpCAM+ and TROP-2+ cell populations. Pathway analysis of the transcription profiles
of human HPCs showed an enrichment and activation of known HPC pathways like Wnt/β-catenin, TWEAK and HGF. Integration of
the HPC niche profile suggests autocrine signalling by HPCs (TNFα, PDGFB and VEGFA) as well as paracrine signalling from the
surrounding niche cells including MIF and IGF-1. In addition, we identified IL-17 A signalling as a potentially novel pathway in HPC
biology. In conclusion, we provide the first RNA-seq-based, comparative transcriptome analysis of isolated human HPCs from ASH
patients and revealed active signalling between HPCs and their surrounding niche cells in ASH livers and suggest that HPCs can
actively contribute to liver inflammation.
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The adult human liver, as part of the gastrointestinal tract, has
a high capacity to regenerate and to restore its liver mass after
liver damage.1 Mild cell loss can be compensated by
proliferation of the epithelial cell compartment, the hepato-
cytes (HCs) and the cholangiocytes, followed by proliferation
of the mesenchymal and endothelial cells.2 However, when
cell loss is too severe and/or the regenerative capacity of the
HCs is impaired, which is the case in many chronic liver
diseases, a third epithelial cell compartment becomes active:
the hepatic progenitor cells (HPCs), which can differentiate
either into HCs or cholangiocytes dependent on the most
damaged cell compartment.2
The widely spread use of alcohol and alcohol abuse in
the world makes alcoholic steatohepatitis (ASH) one of the
leading causes of chronic liver disease and liver failure. The
pathology of ASH ranges from fatty liver, septal fibrosis to
cirrhotic liver and hepatocellular carcinoma. During disease
progression there is increased damaging of HCs and HC
growth arrest, impairing the hepatocellular regeneration of the
liver.3,4 Besides a high activation and proliferation of HPCs, the
ASH liver is also characterised with an inflammatory response
and rapid progression of fibrosis.5 Little is known about the
HPC identity and the mechanisms controlling HPC activation
during ASH development.
HPCs are small cells with a relative large oval nucleus and a
scanty cytoplasm.6 They are situated in the canals of Hering,
the terminal branches of the biliary tree, in the portal tracts.7
Phenotypically, HPCs express markers of (immature) HCs
(e.g. α-fetoprotein) and markers of cholangiocytes (e.g.
cytokeratin K7 and K19). A specific HPC marker has yet to
be found, which is one of the technical hurdles slowing down
human HPC research as it is hindering the development of
good isolation methods.6 Several different approaches have
been reported to obtain HPC-enriched cell populations from
animal livers and human liver tumour tissue. The side
population (SP) technique, for instance, isolates an HPC-
enriched population based on the efflux of the fluorescent
dye Hoechst-33342, due to the high expression of ABC
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(ATP-binding cassette) transporters.8,9 Another method to
sort/isolate HPCs is based on the epithelial membrane marker
EpCAM (epithelial cell adhesion molecule).10 Still, EpCAM
and other cell markers are not uniquely expressed by HPCs
and therefore the obtained cell populations also contain other
cell types like cholangiocytes and HPC-derived intermediate
HCs that express EpCAM as well.
Trophoblast antigen 2 (TROP-2) is a relatively new epithelial
marker and is specifically expressed by activated progenitor
cells in mouse models of liver disease.11 TROP-2 is an
epithelial membrane protein also known as tumour-associated
calcium signal transducer 2 (TACSTD2). It is the only other
tacstd gene family member of TACSTD1, also known as
EpCAM.12 During liver injury in murine models, HPCs (aka
oval cells) start to express TROP-2 and can be used to isolate
oval cells from animal models of liver disease.11 TROP-2
expression in human HPCs has been described within our
group.13,14 To isolate human HPCs, TROP-2 expression and
isolation potential has not been tested yet in alcoholic liver.
In this study, we explored three different HPC isolation
approaches and determined the transcription profiles of the
obtainedSP, EpCAM+ and TROP-2+ cell populations of human
adult ASH explant liver tissue by RNA-sequencing. To gain
further insight into themechanisms involved in HPC activation,
we isolated the HPCs and their niche via laser capture
microdissection (LMD) and compared their transcriptional
profile with HPCs.
Results
TROP-2 expression in healthy and diseased human
liver. TROP-2 has been used previously to isolate HPC
populations from murine livers, without contamination of
cholangiocytes or intermediate HCs.15 To evaluate the
suitability of TROP-2 for the isolation of human HPC
populations, the expression of this membrane protein was
validated with immunohistochemistry in healthy and diseased
human livers. The expression of TROP-2 was compared with
K19 expression, a known and validated HPC marker,13 in
different stages of alcoholic liver disease. In healthy human
liver, low expression of TROP-2 was detected in cholangio-
cytes, while K19 was strongly expressed in these cells
(Figure 1a). As the disease proceeded, cholangiocytes and
the activated HPCs started to express more TROP-2 with the
highest expression of TROP-2 in the cholangiocytes and
ductular reaction of the end-stage diseased liver. Comparison
of the expression of TROP-2 and K19 indicated that both
proteins are expressed by the same cells, namely cholangio-
cytes, HPCs and some intermediate HCs. This colocalisation
was later confirmed by fluorescent immunohistochemical
double staining of K19/TROP-2 (Figure 2a). The same
expression pattern could be detected in end-stage livers with
other aetiologies like primary sclerosing cholangitis, hepatitis
C viral infection and α1-antitrypsin deficiency (Figure 1b).
Fluorescent-activated cell sorting (FACS) analysis showed a
clear TROP-2+ population when a fluorophore-conjugated
TROP-2 antibody and ASH liver cell suspension were used
(Figure 1c). Analysis of the TROP-2+ cell population via
immunohistochemical validation of cytospins demonstrated
that this population consisted of 86% TROP-2+, 91%
EpCAM+ and 71% K19+ cells. (Figure 1d). The degree of
ductular reaction, or the activation of HPCs, in the different
ASH samples, could be correlated with the percentage of
TROP-2+ cells isolated by FACS (Figure 1e); the more
activated HPCs, the higher the ductular reaction score,
which resulted in higher amount of sorted TROP-2+ cells.
Figure 1 Evaluation of TROP-2 expression in human liver and isolation of TROP-2+ cells. (a) Immunohistochemical evaluation of TROP-2 in healthy, early, septal and end-
stage alcoholic liver, compared with the expression of K19 (arrows= TROP-2+ ductular reaction; arrowheads= TROP-2+ cholangiocytes). (b) TROP-2 expression in other end-
stage liver diseases: primary sclerosing cholangitis, hepatitis C and α1-antitrypsin deficiency. (c) FACS analysis of TROP-2+ cell population. (d) Immunohistochemical analysis of
cytospins of TROP-2+ population. (e) Correlation between the ductular reaction score and percentage of the isolated population, shown for TROP-2+ populations
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Taken together, these results demonstrate that human HPCs
express TROP-2 and that it can be used for the isolation of
HPCs from human livers.
Isolation of HPC-enriched populations from ASH livers
based on SP, EpCAM and TROP-2 positivity. The two
membrane markers EpCAM and TROP-2 are expressed in
HPCs and cholangiocytes in human explant livers, demon-
strated by coexpression with K19 on fluorescent immunohis-
tochemical double staining of TROP-2/K19 and EpCAM/K19
(Figure 2a). TROP-2 was mainly located in ductular reactions
and cholangiocytes, while EpCAM was also expressed in a
large part of the intermediate HC population resulting in a
bigger EpCAM+ population than a TROP-2+ population
(Figure 2a). The SP method is a functional isolation method
based on the efflux of Hoechst-33342 by ABC transporters,
like ABCG2. This membrane transporter was expressed
throughout the liver, but although ABCG2 and other ABC
transporters were expressed in HCs, the expression was
higher in HPCs (Figure 2a). To characterise human HPCs
and identify underlying proliferation and differentiation
mechanisms, single-cell suspensions of four different ASH
livers were used to isolate TROP-2+, EpCAM+ or SP cells
from each liver by FACS. Cells were sorted excluding debris,
duplets, CD45+ cells (only in SP) and dead cells using
forward scatter, side scatter, CD45 antibody and propidium
iodide gating (Figure 2b). A schematic overview of the
followed workflow can be found in Supplementary Figure 3.
Immunohistochemical analysis of FACS-sorted HPCs
showed that the isolated HPCs contained relatively low
number of cells not expressing TROP-2, EpCAM or K19,
indicating a successful isolation of human HPCs with all
methods used (Supplementary Figure 4). Sorted cell popula-
tions were processed for RNA-sequencing to compare the
transcriptome of the different isolated HPCs with each other
and the total liver cell population (referred to as total liver).
Transcriptome profiling of SP, EpCAM+ and TROP-2+
HPCs from ASH livers. Principal component analysis
(PCA) showed that the total liver samples were clustered
together, completely separated from the HPC-isolated groups
(Figures 3a and b). Surprisingly, the isolated groups were
clustered based on patient variety, not on the isolation
method. This result was also supported by Pearson's
correlation on the same groups. Although there were still
large similarities between the patients, one patient sample
(patient 1) clearly diverged from the others, which was not
observed in the total liver samples from all the corresponding
patients (Figure 3a).
Figure 2 Isolation and evaluation of SP, EpCAM+ and TROP-2+ population. (a) Immunofluorescent double staining of human ASH liver: TROP-2/K19, K19/EpCAM and
ABCG2/K19. Immunohistochemical evaluation of K19, TROP-2 and EpCAM expression in ASH liver. (b) FACS profiles of SP, EpCAM+ and TROP-2+ populations
Identity of HPCs in ASH
A Ceulemans et al
3
Cell Death and Disease
To identify a possible human HPC gene signature, the
significantly enriched genes from all three isolated groups
were compared with total liver (Figure 3c). A total of 1617
genes or 41.9% of the total number of enriched genes were
common between the threeHPCpopulations, indicating a high
similarity between the HPC-enriched groups. The similarities
between the EpCAM+ and TROP-2+ groups were the highest
(a total of 2097 enriched genes in common or 67.9% of all
enriched genes in EpCAM and TROP-2 groups).
Based on the PCA, Pearson's clustering and the amount of
corresponding genes common in all groups, the three FACS
isolation methods seemed to result in highly similar popula-
tions. A more detailed analysis of these isolated groups
showed that HPC markers like K19, SOX9 and PROM1 were
highly enriched in HPC groups, whereas HC markers such as
ALB, AFP and HNF4A were clearly deprived. In the total liver
group the opposite could be detected: a lower expression of
HPC markers and a higher expression of HC markers.
Analysis of other cell-type-specific genes did not indicate the
presence of immune cells, stellate cells or endothelial cells in
the HPC-enriched groups (Figure 3d). In support of our study,
we performed qPCR validation of the FACS isolated groups
and compared the fold expression with the RNA-sequencing.
Comparison of qPCR andRNA-seq of the same samples gave
the same expression pattern with an enrichment of HPC
markers in SP, EpCAM+ and TROP-2+ populations and
enrichment of HC, stellate cell and immune cell markers in
total liver samples (Supplementary Figure 5).
Gene ontology (GO) analysis on the differential expressed
genes showed variances in GO terms between the differently
isolated populations (Figure 4a). Unique enriched genes for
EpCAM (130 genes) or TROP-2 (106 genes) populationswere
characterised by metabolic GO terms that only contain up to
five genes. In the SP group (394 genes), at least seven GO
terms linked with immune response could be detected, next to
cell metabolism-related pathways. These highly significant
immune-related GOs could indicate the presence of immune
cells within this HPC group, even though CD45+ cells were
excluded during FACS isolation. Immunohistochemical ana-
lysis of cytospins indicated that 3% of the isolated cells were
expressing CD45. The absence of these GOs in the TROP-2+
and EpCAM+ group in combination with only few, low
Figure 3 Evaluation of SP, EpCAM+ and TROP-2+ population. (a) PCA analysis of the different patients and isolation methods. (b) Clustering of the different isolated groups.
(c) Overview of the amount of significant enriched genes in the different isolated groups versus total liver. (d) Marker clustering analysis of different cell types in total liver versus
SP, EpCAM+ and TROP-2+ population
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significant GOs suggested a higher purity was achieved with
these methods. The presence of some immune cells in SP
could also explain the large set of enriched genes specific for
SP (Figure 3c). Nevertheless, more than 1600 enriched genes
(when compared with total liver) were shared with EpCAM and
TROP-2, indicating that the SP containedmainly HPCs. Taken
together, this transcriptome comparison indicated that differ-
ent HPC-enriched populations were being isolated from the
human livers using SP, TROP-2 or EpCAM selection, with
EpCAM- and TROP-2-based isolations as the most selective
methods (Figure 3d). Complete gene lists and extra informa-
tion of the graphs in Figures 3 and 4a can be found in the
supplementary excel file.
Analysis of HPCs from ASH livers confirms involvement
of established activation pathways. IPA analysis was
performed on the differential expressed genes of the HPC-
enriched populations versus total liver in search for pathways
involved in human HPC activation. Previous work of Spee
et al.16 already demonstrated that the presence of pathways
first identified in animal models of liver disease can be
confirmed in human livers, showing, for instance, the
activation of Wnt signalling in proliferating HPCs isolated
through LMD. Here, pathway analysis of RNA-seq data
indicated a highly significant activation of the Wnt/β-catenin
pathway in human HPCs isolated from ASH livers
(Figure 4b). Several other pathways, described in animal
models to steer HPC activation, were also significantly
activated in all human HPC groups like HGF, FGF and
TWEAK signalling17–20 (Figure 4b). We also confirmed
pathways that are less well documented so far for their
involvement in HPC regulation like TGF-β, ErbB and the
Hippo pathway.21,22 These data suggested that these path-
ways, mainly described for mouse HPC biology, were present
and activated in HPCs in human ASH livers. The IPA analysis
resulted also in a list of significant pathways not previously
associated with HPC biology such as PI3K/Akt and integrin-
linked kinase signalling. A list of the common top upregulated
pathways can be found in Supplementary Table 2.
RNA-seq analysis of the HPC niche reveals cell-to-cell
communication with HPCs. We hypothesised that the
activated pathways identified by IPA analysis in the isolated
HPCs could be directly influenced by the surrounding niche
cells.16 LMD was performed to isolate HPCs and their
surrounding niche based on their morphology and K7
immunohistochemistry (Figure 5a). Regions with a high
ductular reaction, excluding lobular ductuli and HCs, were
selected (referred to as the niche). As such, the presence of
certain expression profiles in the close neighbourhood of the
HPCs could shed light on potential interactions between the
niche and the HPCs.
We confirmed that TWEAK was expressed in the niche
(P= 0.0112) and that HPCs could respond to this through the
TWEAK receptor, TNFRSF12A, present in all HPC popula-
tions (P=0.0209; Figure 5b).23 A similar pattern could be
detected when evaluating the expression of FGF7 and its
receptor FGFR2 (resp. P=0.0087; P=0.0248), and HGF and
its receptor MET (resp. P=0.0079; P= 0.0090; Figure 5c).
FGF7 and HGF are expressed in the niche but not by the
progenitor cells themselves, while the HPCs showed enriched
expression of the receptors FGFR2 and MET (Figure 5c).
Potential candidates in the niche are activated stellate cells,
known to express HGF and FGF7.23 Enriched expression of
Figure 4 Pathway analysis of differently expressed genes of the FACS isolated HPC-enriched populations. (a) Differences in significant pathways in the different HPC-
enriched groups and total liver. (b) Different significant (− log(P-value)) pathways linked with HPC activation/proliferation and their activation (z-score) in the different isolated
groups versus total liver. Blue dotted line= significant P-level (0.05). Red dotted line= z-score limit of 1 (z-score41 is activation, z-scoreo1 is inhibition of pathway)
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the neutrophil markers CXCR1, CXCR2 and CCR2 in the
niche, combined with the expression of neutrophil attractant
CXCL1 by HPCs suggested that HPCs were capable of
attracting and recruiting neutrophils into the liver (resp.
P=0.0048; P= 0.0048; P=0.0048; P= 0.0162; Figure 5d).
To identify novel cytokines and growth factors that can
influence HPC activation we searched for potential upstream
regulators using IPA analysis. We identified several cytokine
pathways that were significantly activated in the HPCs and
verified their respective cytokine expression in HPCs and the
niche (Figure 6). A first group consisted of TNFα, PDGFB
and VEGFA, which are cytokines produced by the HPCs
and act as significant upstream regulators in all isolated HPC
populations (resp. P= 0.0107; P=0.3895; P=0.0036). MIF
and IGF-1 formed a second group, whose expression was
enriched in the niche and their pathways were activated in the
HPCs, suggesting that niche cells produced MIF and IGF-1 to
stimulate HPCs (resp. P=0.0641; P= 0.0108; Figure 6).
The IL-17 A signalling as a new pathway involved in HPC
metabolism. One of the top canonical pathways activated in
all three HPC-enriched populations was the IL-17 A pathway
(Figure 7a). When looking at IL-17 A mRNA expression in the
liver, hardly any IL-17 A expression could be detected in the
total liver cell population indicating low expression. On protein
level, IL-17 A-producing cells could be detected in the portal
Figure 5 Comparison of isolation via LMD and FACS isolation. (a) Example of serial sections of K7 positivity and LMD (before and after dissection) of HPC-enriched regions.
(b) Median gene expression (TPM±S.E.M.) of TWEAK and TNFRSF12A. (c) Median gene expression (TPM± S.E.M) of FGF7, FGFR2, HGF and MET. (d) Median gene
expression (TPM±S.E.M.) of CXCR1, CXCR2, CCR2 and CXCL1 (*Po0.05; mean±S.E.M.)
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tracts via immunohistochemical staining. The amount of
IL-17 A+ cells varied between patients but the distribution
showed great similarities: the cells were scattered throughout
the liver but mainly present in the portal tracts, closely to the
HPCs (Figures 7b and c). IL-17 A can activate the IL-17 A
pathway through binding with the receptors IL-17RA and
IL-17RC inducing a signalling cascade resulting in the
production/activation of c-JUN, c-FOS and the expression
of chemokines and interleukins. There were no differences
detected in the expression of IL-17RA and a slightly lower
expression of IL-17RC could be seen in HPCs when
compared with total liver (resp. P=0.7817; P= 0.0687;
Figure 7d) not excluding a possible IL-17 A interaction with
HPCs. The expression of the downstream targets of the
IL-17 A pathway was higher in the HPC-enriched groups in
comparison with the total liver (Figure 7e). Induced genes like
CCL20, CXCL1 and CXCL2 are involved in chemoattraction
of immune cells like macrophages, Th17 cells and
neutrophils,24–26 suggesting that HPCs might be induced
through IL-17 A to stimulate the immune cell response in
the liver.
Discussion
In this paper, we used different approaches to isolate human
HPCs and its niche from ASH livers and performed the first,
RNA-seq-based, comparative transcriptome analysis of iso-
lated human HPCs. We demonstrated that (i) in humans,
TROP-2 is expressed in cholangiocytes and HPCs during liver
disease and can be used to isolate human HPCs; (ii) TROP-2+
and EpCAM+ HPC populations from ASH livers have very
similar transcriptome profiles; (iii) unbiased analysis of the
transcriptome data identified novel pathways involved in
cellular communication between the HPCs and its niche.
As described by Okabe et al.,15 TROP-2 can be used to
isolate activated mouse HPC populations also known as oval
cells, as in mice, TROP-2 is only expressed in activated oval
cells when liver disease is induced. In contrast, in humans, we
detected the expression of TROP-2 in cholangiocytes and
HPCs in healthy livers. When the liver disease progresses and
fibrosis develops, TROP-2 is expressed in cholangiocytes and
in activating and proliferating HPCs. Thus, we demonstrate
that in human livers, EpCAM and TROP-2 are both markers of
cholangiocytes and activated HPCs.
Marker clustering, PCA/Pearson's analysis and immuno-
histochemical validation indicated the successful isolation of
HPC-enriched populations from human ASH livers, which
were used for further analysis. EpCAM and TROP-2 are two
closely related proteins with slightly different expression in the
human liver. Although EpCAM is also expressed in a large
population of intermediate HCs, TROP-2 and EpCAM gene
expression profiles are highly similar, probably because of the
exclusion of most of the larger cells through Percoll gradient
centrifugation. RNA-seq analysis revealed great similarities
between the EpCAM+ and TROP-2+ populations (2097
commonly enriched genes), while SP cells differed substan-
tially from these two HPC populations. This lower transcrip-
tional profile similarity between SP and EpCAM or TROP-2
isolated cells is most likely due to the difference in isolation
method: SP is a functional assay based on the presence and
functionality of ABC transporters, while EpCAM and TROP-2
isolations are based on the presence of membrane proteins.
Still, all HPC-enriched populations are successfully separated
by PCA from their respective total livers. Differences in
activated/inhibited pathways between the isolation methods
could be an indication of the presence of different sub-
populations of HPCs in the human liver. The high amount of
commonly activated genes, however, indicates that the
different populations were highly similar and only different in
some metabolic pathways or immune pathways, perhaps
because of an incomplete exclusion of CD45+ cells in the SP
fraction. Furthermore, SP is technically challenging: an
expensive UV laser is needed, much optimisation is required,
long incubation periods that challenge the cells, the potential
Figure 6 Identification of cytokines and growth factors expressed in human HPCs or in the niche. Upper panel: Different significant (− log(P-value)) cytokines and growth
factors linked with HPC and their activation (z-score) in the different isolated groups versus total liver. Blue dotted line= significant P-level (0.05). Red dotted line= z-score limit of
1 (z-score41 is activation, z-scoreo1 is inhibition of pathway). Lower panel: Median gene expression (TPM± S.E.M.) of TNFα, PDGFB, VEGFA, MIF and IGF-1 (*Po0.05;
mean±S.E.M.)
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toxicity of Hoechst and verapamil and the relative short action
span of verapamil blocking. The potential Hoechst toxicity
could prevent the use of the isolated cells in subsequent
in vitro assays. Isolations based on the presence of membrane
proteins like EpCAM and TROP-2 are less challenging and
less prone to contamination. So, taken into account the
potential difficulties with SP (technically, immune cell contam-
ination) and EpCAM (intermediate HCs) isolation, we prefer
the TROP-2 isolation as it is a relatively easy techniquewithout
many pitfalls and is most likely to result in the most pure and
viable HPC populations.
IPA analysis of the three isolated groups confirmed the role
of several pathways involved in the activation and differentia-
tion of HPCs like the Wnt, TWEAK, TGF-β, HGF and FGF
pathway.17–20,27 The Wnt/β-catenin pathway is involved in the
proliferation of human HPCs as activation of the pathway
leads to the expansion of HPCs.16 TGF-β signalling results in
the release of β-catenin, thereby activating the Wnt pathway
and regulating the activation and differentiation of HPCs.28
TWEAK, HGF and FGF are known inducers of HPC
activation.23 Macrophages and other immune cells like
CXCR4+ T cells can be a source of the elevated TWEAK
levels in diseased livers. Studies have shown that the
activation of TNFRSF12A (FN14, CD266) by TWEAK can
lead to activation and expansion of HPCs.29,30 Takase et al.19
showed that in FGF7-deficient mice HPC expansion after liver
injury was deprived. In contrast to EGFR-mediated NOTCH1
signalling, which controls the biliary commitment of HPCs,
HGF controls the differentiation of HPCs toward HCs via MET-
driven AKT/STAT3 activity.31 The activation of HC lineage
committing pathways, like HGF and Wnt signalling, can be
correlated with the HC regeneration inhibitory effects of
alcohol.32,33 We confirmed the enriched expression of the
receptors in the isolated HPC populations while their ligands
were enriched in the niche (Figure 5), thereby confirming the
importance of these pathways in ASH livers.
In addition to already knownHPC pathways, wewere able to
identify autocrine signals thus far not associated with HPC
biology (Figure 6). One of these autocrine signals is PDGFB,
which is known to modulate neovascogenesis and osteogen-
esis by stimulating mesenchymal stem cells to differentiate
into epithelial cells or osteoprogenitor cells.34,35 VEGFA,
Figure 7 Interleukin-17A (IL-17 A) pathway as a potential player in human HPC activation/proliferation. (a) Significant (− log(P-value)) IL-17 A pathway and the activation
(z-score) in the different isolated groups versus total liver. Blue dotted line= significant P-level (0.05). Red dotted line= z-score limit of 1 (z-score41 is activation, z-scoreo1 is
inhibition of pathway). (b) Immunohistochemical evaluation of IL-17 A+ cells in alcoholic liver: high versus low (arrowheads) infiltration. Comparison of the amount of IL-17 A+ cells
in (peri)portal and parenchyma regions of the liver (average amount of IL-17 A+ cells per high powerfield in parenchyma or (peri)portal region) (*Po0.05; mean±S.E.M.).
(c) IL-17 A+ cells and K19+ cells in the same region on serial slices. (d) Median gene expression (TPM± S.E.M.) of IL-17RA and IL-17RC (*Po0.05; mean± S.E.M.). (e) Median
gene expression of downstream targets of IL-17 A signalling in airway cells
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another autocrine signal, has been described to contribute to
the immobilisation of progenitor cells and the maintenance of
stem cells,36–38 while TNFα, a well-known proinflammatory
cytokine, can promote osteogenic differentiation of mesench-
ymal stem cells.39 Gene expression of these cytokines is
enriched in human HPCs (and not in niche cells) and can
differentially regulate their respective signalling pathways in
HPCs. While HPC-specific knockout studies of these cyto-
kines are necessary to unambiguously establish a role for
these cytokines in HPC biology, our data strongly suggests
that PDGFB, TNFα and VEGFA are part of a autocrine
signalling pathway in HPCs that stimulate activation of
these cells.
We also revealed paracrine signals, like MIF and IGF-1, that
are produced by the niche and stimulate respective pathways
in HPCs. Studies have shown that IGF-1 is crucial for the
terminal osteoblast differentiation of mesenchymal stem
cells40 and can even stimulate the differentiation of mesench-
ymal stem cells towards HC-like cells.41 This suggests that, in
ASH livers, IGF-1 could be released by niche cells to favour
the differentiation of HPCs towards HCs. MIF, on the other
hand, could be important for the expansion of HPCs in ASH as
MIF can promote cell survival, proliferation and self-renewal of
other stem cells such as neural stem cells.42
Modulation of these novel auto- and paracrine HPC signals
in animal models of liver disease will show whether these
cytokines can have an impact on disease progression or HPC
activation. With respect to HPC activation, the TNFα antago-
nist Infliximab could inhibit HPC activation and fibrosis in both
a mouse model of steatosis and cholestasis.43 However, while
early clinical trials with alcoholic hepatitis patients have shown
promising results with the single treatment with Infliximab,44,45
randomised trials using either IFX or Etanercept (soluble TNF
receptor) were disappointing.46,47
Expression profiling of the HPCs and their niche also
suggests an active participation of HPCs in immunomodula-
tion. HPCs express immune cell chemoattractant genes like
CXCL1, while the niche is enriched in immune cell markers,
likeCXCR1 andCCR2, indicative of a recruitment due to these
chemoattractants. We furthermore show that the IL-17 A
pathway is upregulated in all isolated HPCs. Many studies
have found a link between IL-17 A and fibrogenesis. In a
mouse model of biliary atresias, IL-17 A was highly produced
by γδ cells in the liver, thereby inducing inflammation and
destruction of the biliary system.48 In a study of Meng et al.,49
mouse models and cell lines were used to demonstrate that
IL-17 A could activate Küpffer cells and stellate cells through
the activation of Stat3 signalling and as such induce fibrosis
and inflammation in the diseased liver. This was confirmed by
Tan et al.50 who showed that knocking out IL-17RA in mice
reduced inflammation and fibrosis in a CCl4 liver disease
model. In our study, human HPCs showed an enhanced
IL-17 A pathway, indicating a potential interaction between
HPCs and immune cells. Previous studies on colonic epithelial
cells have shown that IL-17 A represses TNFα-induced
expression of CXCL10, CXCL11 and CCL5, but, on the other
hand, synergised with TNFα for the induction of genes like
CXCL1.51 Our results show a similar trend; HPCs express and
respond to TNFα (Figure 5), while the expression of CXCL10,
CXCL11 andCCL5 (resp. P= 0.7340; P= 0.4520; P= 0.0146)
are not elevated in HPCs in comparison with total liver while
CXCL1 is elevated (Figure 4d and Supplementary Figure 6).
This could suggest that in ASH livers IL-17 A might regulate
the expression of TNFα-induced genes in HPCs. Although our
data in combination with literature indicates a potential role for
IL-17 A signalling, further evidence from in vitro/in vivo
functional work is needed to proof and unravel the interaction
with HPCs.
In conclusion, we successfully isolated three distinct HPC
cell populations from human ASH livers. RNA sequence
analysis of HPCs with their niche revealed thus far unknown
signalling cascades involved in HPC activation and cell-to-cell
communications between the niche and HPCs in ASH livers
and suggest that HPCs can actively contribute to liver
inflammation.
Materials and Methods
Human liver samples. Seven explant livers of patients diagnosed with ASH
between 2009 and 2015 at the University Hospitals in Leuven (Belgium) were
included in this study. From these seven patients, the SP, EpCAM+ and TROP-2+
populations and whole liver extracts from four samples, which met the RIN (≥7) and
yield (≥200 ng/μl) requirements, were used for RNA-sequencing analysis. The
same samples were used for the LMD part, although one of the samples did not
meet the required quality and was excluded from LMD isolation. Immediately after
surgical removal of the diseased liver during orthotopic liver transplantation, tissue
biopsies were taken and fixed in 6% formalin-fixed, paraffin-embedded (FFPE)
samples or snap frozen in isopentane-cooled liquid nitrogen. Another part of the
explant liver was cut in small blocks of 1 mm by 1 mm to be frozen overnight
in Recovery Cell Culture Freezing Medium (Life Technologies, Paisley, UK) on
− 80 °C, after which the samples were stored in liquid nitrogen. Only end-stage
ASH livers without tumour nodules and previous chemo and/or RFA treatment were
selected in the study. FFPE samples of healthy liver, early, septal and late-stage
alcoholic livers were collected from the University Hospitals' databank. The study
was approved by the ethical committee of the University Hospitals. Detailed
background information of the patients used for RNA-sequencing can be found in
Supplementary Table 1.
Immunohistochemistry. Immunohistochemistry was performed on paraffin-
embedded sections (5 μm) or cryostat cut sections (4 μm). The snap-frozen
sections were fixed in acetone for 10 min. Epitope retrieval was performed on the
paraffin-embedded sections in a pre-treatment module (Dako, Heverlee, Belgium)
according to the manufacturer’s instructions in citrate buffer (pH 6) or in EDTA-Tris
buffer (pH 9). After blocking the endogenous peroxidase activity with Dual
Endogenous-Enzyme Blocking Reagent (Dako, Heverlee, Belgium), the sections
were incubated with the primary antibody against TROP-2 (1/20; Abcam,
Cambridge, UK), EpCAM (Ber-Ep4, ready-to-use; Dako), keratin K19 (1/100;
Dako), ABCG2 (BCRP; 1/5; Monosan, Sanbio, Uden, Belgium ), K7 (ready-to-use;
Dako) for 30 min at RT. Following PBS washing (pH 7.2), the slides were incubated
with horseradish peroxidase-labelled EnVision FLEX System (Dako) for 30 min at
RT. IL-17 A (1/50; R&D Systems, Minneapolis, MN, USA) had an overnight
incubation, followed by 1 h incubation of horseradish peroxidase-labelled goat anti-
serum (1/20; Dako). After washing with PBS, the peroxidase activity in FFPE
sections was detected using 3.3′-diaminobenzidinen, DAB (Dako) as a substrate,
revealing a brown reaction product, and in frozen sections using 3-amino-9-
ethylcarbazole, AEC (Dako), revealing a red reaction product. Finally, the sections
were counterstained with Mayer’s haematoxylin and mounted. Pictures were taken
by Leica DMLB (Leica Microsystems, Herborn, Germany).
Immunofluorescence. To identify the expression profile of TROP-2+,
EpCAM+ and ABCG2+ cells, immunofluorescent double staining was performed
on 4 μm cryosections. In series, the primary antibodies were incubated against K19
(1/100; Dako) and EpCAM (Ber-Ep4, ready-to-use; Dako), K19 (1/100; Dako) and
TROP-2 (1/20; Abcam), K19 (1/100; Dako) and ABCG2 (BCRP; 1/10; Monosan).
Alexa Fluor 488 goat anti-mouse and Alexa Fluor 568 goat anti-mouse (Life
Technologies, Brussels, Belgium) were used as secondary antibodies and were
incubated for 30 min at RT. Counterstain was performed with 4',6-diamidino-2-
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phenylindole (1/10 000; Invitrogen, Breda, The Netherlands) for 15 min. PBS was
used for the rinsing steps and the slides were covered by ProLong Gold Antifade
Reagent (Life Technologies, UK). Pictures were taken by Zeiss Axioplan (Carl Zeiss,
Oberkochen, Germany).
Tissue processing and cell isolation
Tissue dissociation: Tissue dissociation and SP isolation were done as
described previously.8 The samples stored in liquid nitrogen were thawed at 37 °C
and washed with Hank’s balanced salt solution (Life Technologies, UK). After
dissociation using Liberase Blendzyme 3 (Roche, Basel, Switzerland) at a
concentration of 0.8 Wunsch unit/ml during 1 h at 37 °C, the samples were filtered
with a 70 μm nylon mesh filter (BD Biosciences, Erembodegem, Belgium) and
gradient centrifugation based on 15% Percoll/Hank’s balanced salt solution (100 × g
for 15 min). Finally, the pelleted cells were resuspended in HepatoZYME-SFM (Life
Technologies, UK) with 1% penicillin/streptomycin (Life Technologies, UK) added to
obtain a single-cell suspension.
Cell isolation based on FACS: To isolate the SP of the single-cell suspension,
the cells were incubated with 5 μg/ml Hoechst-33342 (0.1 mg/ml; Sigma-Aldrich, St.
Louis MO, USA) for 90 min at 37 °C exactly under continuous agitation. A control
sample was obtained by incubating the cells with the transport blocker Verapamil
(100 μM; Sigma-Aldrich) 20 min before the Hoechst-33342 incubation. As such, the
active efflux and SP phenotype could be assessed. To exclude CD45+ cells from
isolation, the sample was incubated with an antibody against CD45 conjugated with
R-phycoerythrin for 30 min (10 μl per million cells; Ab Serotec, Bio-Rad, Puchheim,
Germany).
To isolate EpCAM+ and TROP-2+ cells from the cell suspension, the samples were
separately incubated, respectively, with a PE-conjugated antibody against EpCAM
(10 μl per million cells; R&D Systems, Minneapolis, MN, USA ) or an
allophycocyanin-conjugated antibody against TROP-2 (10 μl per million cells; R&D
Systems) for 30 min on ice. Aspecific binding of the antibodies was prevented by
incubating the samples for 10 min with Fc Blocking Reagent (1/10; BioLegend,
London, UK) before antibody incubation.
Propidium iodide (2 μg/ml; Sigma-Aldrich) was added just before FACS analysis to
all samples to exclude dead cells. The cell samples were analysed and sorted with a
FACSAriaII (BD Biosciences) excluding debris, duplets, CD45+ and dead cells by
forward scatter, side scatter, CD45 antibody positivity and propidium iodide gating
(Supplementary Figure 1). The sorted cells (SP, EpCAM+ and TROP-2+ cells) were
collected in HepatoZYME-SFM (Life Technologies, UK). A part of the sorted cells was
lysed in RTL plus buffer (Qiagen, Hilden, Germany) with 1% β-mercaptoethanol
(Sigma-Aldrich) and stored in − 80 °C until mRNA extraction.
Validation of FACS isolated cells via cytospin and correlation with DR
score: Part of the sorted cells was fixed in BD CytoRich System (BD Biosciences)
and processed into cytospins for immunohistochemical validation. The size of the
isolated populations was correlated with the ductular reaction in each of the
corresponding samples. The ductular reaction or the activation of the HPCs of each
sample was assessed by the Ductular Reaction Score, which is the average amount
of HPCs (visualised with TROP-2 staining) counted per ten high powerfields.
Cell isolation with LMD: Snap-frozen liver samples were used to obtain 10-μm-
thick liver sections with cryostat microtomy, which were mounted on DNase- and
RNase-free PET-membrane-coated metal frame slides (1.4 μm; Leica, Herborn,
Germany). The sections were stored at − 80 °C. Cryosections were stained with a
fast cresyl violet staining. Based on this cresyl violet staining (cresyl violet, 0.2 g/
100 ml; Sigma-Aldrich) and a keratin 7 immunohistochemical staining of a
consecutive slide, HPC-rich areas in the liver were visualised and identified. After
which, the areas were microdissected using a Leica LMD 6500 system (Leica
Microsystems). The dissected fragments were collected on the cap of PCR tubes
filled with 20 μl RLT plus buffer (Qiagen) with 1% 2-mercaptoethanol (Sigma-
Aldrich). After dissection, the samples were vortexed for 30 s and stored at − 80 °C
until further processing. The total handling time needed per slide was kept under
20 min.
mRNA extraction and RNA sequence analysis. Besides mRNA
extraction from the FACS and LMD groups, 10-μm-thick whole liver tissue slides,
sectioned from frozen tissue, were homogenised and lysed in RTL plus buffer with
1% 2-mercaptoethanol. Total mRNA from whole liver, FACS and microdissection
samples was extracted using the RNeasy Plus Micro Kit (Qiagen) according to the
manufacturer’s instructions. An Agilent Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA), using RNA Pico Chip, was used to analyse the quantity and
quality of the mRNA. Four patients of the FACS isolation part and three patients of
the LMD isolation part with a high yield and an RIN value between 6 and 8 were
chosen to be used for high-throughput RNA sequence analysis. Quality control and
RNA-sequencing were performed at the VIB Nucleomics Core (http://www.
nucleomics.be; Leuven, Belgium).
RNA-seq data processing. First, quality control on all fastq files was
performed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc).
Each fastq file was trimmed and filtered to remove adaptors, polyN nucleotides and
low-quality sequences and subsequently confirmed by performing a second quality
control. All reads were mapped by Tophat2 on the Homo sapiens genome h19,
which was downloaded from the UCSC website (http://hgdownload.cse.ucsc.edu).
Transcript compilation was performed using Cufflinks with homo sapiens hg19
UCSC transcript annotation. Differential expression was calculated by Cuffdiff and
subsequently we converted FPKM to TPM (median gene expression) using
RStudio. The data were further analysed with IPA (Inguinity Pathway Analysis) and
Bioconductor.52 Tophat2, Cufflinks and Cuffdiff were performed within Genepattern
(Supplementary Figure 2).
Data visualisation. Heatmaps, Venn diagrams, Pearson's correlation, PCA
and GO analysis was performed using the Bioconductor. FACS analysis plots were
carried out with FlowJo (FLOWJO LLC, Ashland, OR, USA). Photoshop (version CC
2017; Adobe, San Jose, CA, USA) was used to brighten and sharpen the
immunohistochemical pictures.
Pathway analysis. The resulting data set of the high-throughput RNA-
sequencing was analysed in IPA. Only enriched genes (fold change 42 and
Po0.05) in EpCAM, TROP-2 and SP data sets compared with the total liver were
imported. Within IPA, the canonical pathways, regulatory effects and upstream
regulators were analysed.
Statistical analysis. Significance of all the RNA-seq data was calculated by a
nonparametric Kruskal–Wallis one-way ANOVA. Significance of the IL-17 A+ cells in
parenchyma versus (peri-)portal regions was calculated by a Mann–Whitney U-test.
Statistical analysis was performed with Statistica (version 9, StatSoft. Inc., Tulsa,
OK, USA) with a significance level of αo0.05.
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